AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03012451 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Advancing Adolescents
Description: The Advancing Adolescents programme is a structured 8-week psychosocial intervention for adolescents in humanitarian crises, based on profound stress attunement processes. It features three elements that are widely viewed as important to support youth adjustment in contexts of complex emergencies: (i) safety: establishment of a 'safe space' within the community as a base for activities and site of protection; (ii) support: facilitation of social support and self-expression; and (iii) structured activities: access to scheduled group activities.
Study NCT02228486 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: tDCS
Description: 2 mA (verum group) over the left dorsolateral prefrontal cortex (F3, anodal), 15 min; 10 seconds ramp in verum and sham group (see also above)
Study NCT02228486 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Cue Exposure Therapy
Description: 5 weeks (9 sessions) of cue-exposure therapy with preferred alcoholic beverage (see also above)
Study NCT02228486 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cue Exposure Therapy
Description: 5 weeks (9 sessions) of cue-exposure therapy with preferred alcoholic beverage (see also above)
Study NCT02469480 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FerInject
Description: FerInject: max. 2.000 mg of ferric carboxymaltose over max. 2 weeks (max. 1.000 mg per week).
Study NCT02469480 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ferro sanol
Description: 200 mg ferro sanol per day over 12 weeks
Study NCT01372930 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etanercept
Description: Etanercept 25mg in 1ml(subcutaneous injection)at 2h and 72h after PCI
Study NCT01372930 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: saline
Description: saline 1ml(subcutaneous injection) at 2h and 72h after PCI
Study NCT02997345 — intervention group
Intervention type: OTHER
Intervention: There is no intervention associated with this study.
Description: There is no intervention associated with this study.
Study NCT02167594 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Flortaucipir F18
Description: IV injection, 370 megabecquerel (MBq) (10 mCi)
Study NCT02167594 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Brain PET scan
Description: positron emission tomography (PET) scan of the brain 75-105 minutes post-injection
Study NCT03986463 — intervention group
Intervention type: OTHER
Intervention: Circulating tumour DNA (ctDNA)
Description: Circulating tumour DNA (ctDNA) will be isolated from blood samples
Study NCT03811977 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Lutein syrup
Description: 12- week dietary supplementation with lutein syrup (20 mg lutein/day)
Study NCT03811977 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo syrup
Description: 12- week dietary supplementation with placebo syrup (0 mg lutein/day)
Study NCT01896479 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabozantinib (XL184) 140 mg
Study NCT06780956 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional
Description: conventional drilling protocol using full sequence
Study NCT06780956 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: simplfied
Description: 3 burrs for implant placment
Study NCT06781671 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ComfortTheory
Description: Structured nursing interventions based on the Comfort Theory were applied to patients in the intervention group.~Patients were mobilized at least once during the day. Auxiliary materials believed to increase patient comfort, such as tablet computers, wired headphones, sleep headphones, and sleep masks, were provided.~Patients had face-to-face meetings with their families during the day and video calls in the evening.~Care interventions were minimized as much as possible for patients between 24:00-07:00 at night, and treatments were carefully planned around these hours.~Blood sampling was performed at 23:00 at night, and X-rays were taken at 07:00 in the morning.~The Patient Identification Form, General Comfort Scale, and Intensive Care Unit Environmental Stressor Scale were administered face-to-face by the researcher 48 hours after the patient\&amp;amp;amp;#39;s admission to the intensive care unit.
Study NCT00192517 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: MEDI-522
Description: 4 mg/kg (for 12 weeks based on patient's weight, to the nearest kg, obtained on Study Day 0)
Study NCT00192517 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 4 mg/kg(for 12 weeks based on patient's weight, to the nearest kg, obtained on Study Day 0)
Study NCT00359814 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolatmofetile
Description: Mycophenolatmofetile administration: was started with 250 mg/daily at day 1, the start dose was increased about 250 mg/daily every week till 2 g/daily
Study NCT00359814 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclosporin A
Description: Cyclosporin A reduction: Cyclosporin A trough level reduction started after week 8. The new target range was 50 to 90 ng/ml
Study NCT03546478 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 99mTc-ABH2
Description: 99mTc-ABH2 were injected into the patients before the SPECT/CT scans
Study NCT02606877 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nintedanib
Study NCT01896479 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabozantinib (XL184) 60 mg
Study NCT01896479 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo tablet
Study NCT01896479 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo capsule
Study NCT02578277 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CYP and transporter probe substrates
Description: Cocktail of CYP (cytochrome P450) and transporter probe substrates
Study NCT02578277 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-955176
Description: BMS-955176
Study NCT02578277 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-955176 plus CYP and transporter probe substrates
Description: BMS-955176 plus the cocktail of CYP and transporter probe substrates
Study NCT04198701 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Medtronic PulseSelect Pulsed Field Ablation (PFA) System
Description: Adult subjects with a history of drug refractory recurrent symptomatic atrial fibrillation (AF) will undergo ablation of pulmonary veins and confirmation of entrance block and, where assessable, exit block with the PulseSelect PFA System.
Study NCT02606877 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pirfenidone
Study NCT01856634 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 100 mg Delamanid
Description: 100 mg Delamanid BID for 10 days
Study NCT01856634 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 50 mg Delamanid
Description: 50 mg Delamanid BID for 10 days
Study NCT01856634 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 25 mg Pediatric Formulation Delamanid
Description: 25 mg Pediatric Formulation Delamanid BID for 10 days
Study NCT01856634 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 10 mg Delamanid Pediatric Formulation
Description: Patients > 10 kg will receive DPF 10 mg BID for 10 days
Study NCT01856634 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5 mg Delamanid Pediatric Formulation
Description: Patients > 8 kg and ≤ 10 kg will receive DPF 5 mg BID for 10 days~Patients ≤ 8 kg will receive DPF 5 mg QD for 10 days
Study NCT01856634 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Optimized Background Regimen
Description: Selection and administration of the treatment medications (i.e. OBRs) will be based on WHO's Guidelines for the programmatic management of drug-resistant TB, in conjunction with national TB program guidelines in each country
Study NCT03239808 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Incremental haemodialysis
Description: It consists in reducing the frequency or number of sessions per week with which patients start the HD treatment. The experimental group will start with one session/week, then the number of weekly sessions will be increased to two and later to three as per criteria for progression
Study NCT03239808 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional haemodialysis
Description: It is controlled through usual clinical practice, based on starting the HD treatment with three sessions per week (control group).
Study NCT00677872 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PRX-08066
Study NCT03207152 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Influenza A/California/04/09
Description: Good Manufacturing Practices-certified Influenza A/California/04/09 3.5x10(4) TCID50 in 1 mL in DPBS delivered by intranasal drops
Study NCT03802422 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin B12
Description: Ultrasound-guided hydrodissection with 3cc Vitamin B12 (methycobal, 500μg/ml) between carpal tunnel and median nerve.
Study NCT03802422 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: Ultrasound-guided hydrodissection with 3cc 0.9% normal saline between carpal tunnel and median nerve.
Study NCT01411397 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: SURGERY
Description: REPAIR OF STRANGULATED HERNIA with intestinal resection
Study NCT01411397 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: mesh repair
Description: mesh repair of strangulated hernia without resection
Study NCT03938662 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: formulation containing S-Adenosyl methionine and choline
Description: Patients will be administered with formulation containing S-Adenosyl methionine and choline once daily for the period of 24 weeks.
Study NCT02215928 — intervention group
Intervention type: GENETIC
Intervention: mutation analysis
Description: Correlative studies
Study NCT02215928 — intervention group
Intervention type: OTHER
Intervention: cytology specimen collection procedure
Description: Correlative studies
Study NCT02215928 — intervention group
Intervention type: OTHER
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT03938662 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo of same appearance, colour and taste,
Study NCT02241850 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: High intensity training
Description: 9 weeks of supervised high intensity training
Study NCT04223167 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Red Bull Energy Drink
Description: 473 ml Reb Bull Energy Drink
Study NCT04223167 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Water
Description: 473 ml Water
Study NCT04373980 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: phototherapy
Description: estimate CD4 and CD8 subsets in neonates with unconjugated hyperbilirubinemia after exposure to phototherapy
Study NCT02131467 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Perampanel
Description: oral drug
Study NCT04792138 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: VERDICT MRI
Description: Advanced Diffusion Model
Study NCT04792138 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Luminal Index Imaging
Description: Advanced T2 mapping
Study NCT00562510 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Raltegravir
Description: Raltegravir 400 mg BID added to stable HAART
Study NCT03004677 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard Care
Description: Infants will receive regular care in the NICU. Parents may practice SSC if they like. Parents will note if, with whom, and for how long they provide SSC.
Study NCT03787212 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MiBo ThermoFlo
Description: Test Device
Study NCT00562510 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo BID added to stable HAART
Study NCT02393599 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lorcaserin
Description: 10 mg 2 times per day from Day 3 to 9 and one time on Day 10
Study NCT02393599 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 10 mg 2 times per day from Day 3 to 9 and one time on Day 10
Study NCT02393599 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cocaine Infusion
Description: Screening / Session 1, Study Day -2: 20 mg cocaine, followed by a saline infusion, followed by 40 mg cocaine Baseline/ Session 2, Study Day 1: Saline or 20 mg cocaine followed by either 20 mg cocaine or saline Baseline / Session 3, Study Day 2: Saline or 40 mg cocaine followed by either 40 mg cocaine or saline Treatment / Session 4, Study Day 9: Saline or 20 mg cocaine followed by either 20 mg cocaine or saline Treatment / Session 5, Study Day10: Saline or 40 mg cocaine followed by either 40 mg cocaine or saline
Study NCT02057237 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mitotane
Description: Mitotane will be administered at a starting dose of 1.5 g/day and increased in case of good gastrointestinal tolerance every 3rd day by 0.5 g up to a maximal dose of 5.0 g and then adjusted according to blood concentrations monthly and tolerability, up to a maximum of 10g daily
Study NCT01742351 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Guided internet-based cognitive behavior therapy
Study NCT00991627 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine
Description: 10 mg of a 5 mg/ml hyperbaric solution, intrathecally
Study NCT00836862 — intervention group
Intervention type: OTHER
Intervention: Biologic specimens
Description: Banking of serum, DNA and tissue
Study NCT02271035 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Deflux
Description: Deflux will be injected through the working channel of the cystoscope using a special needle into the submucosal space of the ureteral orifice (Deflux to one ureteral orifice and Vantris to the other side). The technique that will be used is HIT (Hydrodistention Implantation Technique)+ STING
Study NCT02271035 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vantris
Description: vantris will be injected through the working channel of the cystoscope using a special needle into the submucosal space of the ureteral orifice (Deflux to one Vantris to the other side). The technique that will be used is HIT (Hydrodistention Implantation Technique)+ STING
Study NCT03636386 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Percutaneous microelectrolysis
Description: 284/5000 Application of Direct Current through an acupuncture needle with intensities in microamps (μA) in the PGm of the upper trapezius muscle. The acupuncture needle will correspond to the negative electrode or cathode. The intensity of work will be 610μA at the myofascial trigger point.
Study NCT00991627 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine
Description: 10 mg of a 5 mg/ml hyperbaric solution, intrathecally
Study NCT00991627 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Morphine
Description: 200 µg of a 100 µg/ml solution, intrathecally
Study NCT00991627 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Morphine
Description: 200 µg of a 100 µg/ml solution, intrathecally
Study NCT03636386 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ultrasound therapy
Description: Application of conventional ultrasound (US) on PGm with a frequency of treatment 1MHz, intensity of 1.5W / cm2, ERA 5cm2, Duty Cycle 100%, treatment time 6 minutes.
Study NCT03636386 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ultrasound therapy
Description: Application of conventional ultrasound (US) on PGm with a frequency of treatment 1MHz, intensity of 1.5W / cm2, ERA 5cm2, Duty Cycle 100%, treatment time 6 minutes.
Study NCT00991627 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lactated Ringer's solution
Description: 25 ml/min intravenously
Study NCT02873182 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Autonomic nervous system monitoring
Description: Two intracorporal electrode needles will be inserted beneath the skin of the genitalia. After insertion, the electrodes will be secured and connected by leads to two standard neurophysiological devices for differential amplification, display, and storage. Smooth muscle free-running (continuous) and stimulated EMG will be recorded.
Study NCT02118324 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exergaming Program
Description: Participants will exercise through exergaming play.
Study NCT02545179 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: web-based daily care training
Description: 12 week interactive web based caring training education
Study NCT00991627 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lactated Ringer's solution
Description: 25 ml/min intravenously
Study NCT00991627 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ephedrine, continuous infusion
Description: 37.5 mg/h intravenously
Study NCT00991627 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ephedrine, bolus
Description: 6.25 mg IV bolus prn.~Hypotension defined according to study protocol for each arm.
Study NCT00991627 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ephedrine, bolus
Description: 6.25 mg IV bolus prn.~Hypotension defined according to study protocol for each arm.
Study NCT00991627 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atropine
Description: 0.1 mg/kg iv bolus prn~Bradycardia defined as 50% drop in heart rate from baseline values.
Study NCT00991627 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atropine
Description: 0.1 mg/kg iv bolus prn~Bradycardia defined as 50% drop in heart rate from baseline values.
Study NCT03870581 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: AI-based social software management model
Description: a AI-based miniprogram, embedded in the Wechat social software, to manage participants' warfarin therapy, such as dose adjustment, INR monitoring alert, etc.
Study NCT03870581 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Human-based social software management model
Description: a Human-based miniprogram, embedded in the Wechat social software, to manage participants' warfarin therapy, such as dose adjustment, INR monitoring alert, etc.
Study NCT03787212 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Bruder Mask
Description: Control Device
Study NCT01319929 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2828360
Description: Administered orally
Study NCT01319929 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Administered orally
Study NCT00925171 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pulmonary Intervention
Description: Maintenance programme of 2 hours duration, every 3 months. During the first hour patients will describe the extent to which they have been able to continue with their exercises at home on an individual basis and ways of enhancing adherence to this training will be discussed. Positive re-enforcement will be provided. Patients with suspected depression or social isolation will be referred to their GP for additional management. Patients will be advised on dyspnoea management strategies, especially controlled breathing combined with supervised activity exertion on activities relevant to their daily living. This will be followed by 1 hour of supervised strength and endurance training including walking, cycling, standing from sitting, arm exercises using dumbbells and step-ups. Patients will receive a written report on their progress by their physician and copied to their GP. This will be in addition to the standard advice given to the control group.
Study NCT01986647 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: On the Move exercise - exercise leader
Description: exercise physiologists
Study NCT01986647 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard program - exercise leader
Description: This is an impairment-based exercise program focusing on flexibility, strength and endurance and is taught by research staff who are PTs, PTAs, or exercise physiologists
Study NCT01986647 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: On the Move exercise - staff activity personnel
Description: this is a group exercise program focusing on the timing and coordination of walking. The program is taught by a person from the facility that the research team trained.
Study NCT01986647 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard program - staff activity personnel
Description: This is an impairment-based exercise program focusing on flexibility, strength and endurance and is taught by a member of the facility that the research staff trained.